The first generation of CXCR4 antagonist AMD3100 inhibited the migration of AML blasts induced by SDF‐1 and their proliferation in vitro and reversed the enhanced engraftment of AML blasts into NOD/SCID mice mediated by SDF‐1.55 This evidence concerns the gene CXCL12 and acute myeloid leukemia.